Whitehouse Laboratories Announces Development of Container Testing Center - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Whitehouse Laboratories Announces Development of Container Testing Center



Untitled Document

Whitehouse Laboratories announced the expansion of a new laboratory dedicated to container testing. The expansion will include will a 5000 ft2 laboratory for routine container testing and a Container Closure Integrity Test (CCIT) facility. The laboratory is expected to be complete by February 1, 2014.

The laboratory will contain all instruments required to meet the new USP routine testing directives expected in 2014. In addition, the CCIT laboratory will provide method development, validation, and testing services, which include helium flow, vacuum decay, electrical conductivity, laser diffraction, and residual seal force. The facility will also include onsite capping ability and a full-service package distribution laboratory. The laboratory will be under the direction of Brian Mulhall, who has over 20 years of container and package testing experience.

Source: Whitehouse Laboratories

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here